Immunic Analyst Ratings
Immunic Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/27/2023 | 129.36% | Wedbush | → $5 | Reiterates | Outperform → Outperform |
| 01/31/2023 | 129.36% | Wedbush | → $5 | Assumes | → Outperform |
| 10/21/2022 | 129.36% | SVB Leerink | $9 → $5 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1092.66% | HC Wainwright & Co. | → $26 | Assumes | → Buy |
| 08/08/2022 | 1505.5% | Aegis Capital | $40 → $35 | Maintains | Buy |
| 06/03/2022 | 312.84% | SVB Leerink | $45 → $9 | Maintains | Outperform |
| 05/18/2022 | 1688.99% | Piper Sandler | $71 → $39 | Maintains | Overweight |
| 09/07/2021 | 1046.79% | HC Wainwright & Co. | $40 → $25 | Maintains | Buy |
| 04/15/2021 | 2422.94% | Aegis Capital | → $55 | Initiates Coverage On | → Buy |
| 03/24/2021 | 2422.94% | JMP Securities | → $55 | Initiates Coverage On | → Market Outperform |
| 10/02/2020 | 1964.22% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 08/26/2020 | 3156.88% | Piper Sandler | → $71 | Initiates Coverage On | → Overweight |
| 08/21/2020 | 2468.81% | HC Wainwright & Co. | $60 → $56 | Maintains | Buy |
| 08/03/2020 | 2652.29% | HC Wainwright & Co. | $45 → $60 | Maintains | Buy |
| 07/20/2020 | 1734.86% | BMO Capital | → $40 | Initiates Coverage On | → Outperform |
| 06/05/2020 | 2606.42% | Wedbush | → $59 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 1964.22% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
| 08/12/2019 | 1734.86% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 07/11/2019 | 1734.86% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/27/2023 | 129.36% | Wedbush | → 5 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 01/31/2023 | 129.36% | Wedbush | → 5 美元 | 假设 | → 跑赢大盘 |
| 2022 年 10 月 21 日 | 129.36% | SVB Leerink | 9 美元 → 5 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 09/19/2022 | 1092.66% | HC Wainwright & Co. | → 26 美元 | 假设 | → 购买 |
| 08/08/2022 | 1505.5% | 宙斯盾资本 | 40 美元 → 35 美元 | 维护 | 购买 |
| 06/03/2022 | 312.84% | SVB Leerink | 45 美元 → 9 美元 | 维护 | 跑赢大盘 |
| 05/18/2022 | 1688.99% | 派珀·桑德勒 | 71 美元 → 39 美元 | 维护 | 超重 |
| 09/07/2021 | 1046.79% | HC Wainwright & Co. | 40 美元 → 25 美元 | 维护 | 购买 |
| 2021 年 4 月 15 日 | 2422.94% | 宙斯盾资本 | → 55 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 3 月 24 日 | 2422.94% | JMP 证券 | → 55 美元 | 启动覆盖开启 | → 市场跑赢大盘 |
| 2020 年 2 月 10 日 | 1964.22% | SVB Leerink | → 45 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 08/26/2020 | 3156.88% | 派珀·桑德勒 | → 71 美元 | 启动覆盖开启 | → 超重 |
| 08/21/2020 | 2468.81% | HC Wainwright & Co. | 60 美元 → 56 美元 | 维护 | 购买 |
| 2020 年 3 月 8 日 | 2652.29% | HC Wainwright & Co. | 45 美元 → 60 美元 | 维护 | 购买 |
| 2020 年 7 月 20 日 | 1734.86% | BMO 资本 | → 40 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 2020 年 5 月 6 日 | 2606.42% | Wedbush | → 59 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 05/11/2020 | 1964.22% | HC Wainwright & Co. | → 45 美元 | 启动覆盖开启 | → 购买 |
| 08/12/2019 | 1734.86% | 查丹资本 | → 40 美元 | 启动覆盖开启 | → 购买 |
| 2019 年 11 月 7 日 | 1734.86% | 查丹资本 | → 40 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Immunic (IMUX)?
Immunic (IMUX) 的目标价格是多少？
The latest price target for Immunic (NASDAQ: IMUX) was reported by Wedbush on July 27, 2023. The analyst firm set a price target for $5.00 expecting IMUX to rise to within 12 months (a possible 129.36% upside). 5 analyst firms have reported ratings in the last year.
Wedbush于2023年7月27日公布了Immunic（纳斯达克股票代码：IMUX）的最新目标股价。这家分析公司将目标股价定为5.00美元，预计IMUX将在12个月内升至12个月内（可能上涨129.36％）。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Immunic (IMUX)?
分析师对Immunic（IMUX）的最新评级是多少？
The latest analyst rating for Immunic (NASDAQ: IMUX) was provided by Wedbush, and Immunic reiterated their outperform rating.
Immunic（纳斯达克股票代码：IMUX）的最新分析师评级由Wedbush提供，Immunic重申了其表现跑赢大盘的评级。
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
Immunic（IMUX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Immunic的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Immunic的最后一次评级是在2023年7月27日提交的，因此您应该预计下一个评级将在2024年7月27日左右公布。
Is the Analyst Rating Immunic (IMUX) correct?
分析师评级 Immunic (IMUX) 是否正确？
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a reiterated with a price target of $0.00 to $5.00. The current price Immunic (IMUX) is trading at is $2.18, which is within the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的Immunic（IMUX）评级得到了重申，目标股价为0.00美元至5.00美元。Immunic（IMUX）目前的交易价格为2.18美元，在分析师的预测区间内。